Dynavax Technologies Corporation's flagship product, Heplisav-B, continues to increase market share consistently in a growing ...

A third dose of COVID-19 vaccine offered essential workers some protection from developing long COVID during Omicron variant ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

Health agencies, counties and state officials have been resisting efforts to provide booster jabs to Americans this fall.

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s underwhelming market share for its COVID ...